HVEM (TNFRSF14) functions as a bidirectional immune checkpoint switch, engaging both co-stimulatory and co-inhibitory ligands including BTLA, LIGHT, and lymphotoxin-α, making it a critical node in tumor immune evasion studies. This recombinant mouse TNFRSF14 encompasses the extracellular ligand-binding domain (aa 39–207) with a C-terminal Fc tag, expressed in mammalian cells to preserve native disulfide bonding and glycosylation essential for proper CRD folding and ligand recognition. Functional ELISA confirms an ED50 of 1.17 μg/ml for human BTLA binding, providing validated evidence that supports use in receptor-ligand interaction assays, competitive inhibition studies, blocking antibody screening, and affinity characterization by SPR or BLI. Purity exceeding 95% by SDS-PAGE combined with endotoxin levels below 1.0 EU/μg satisfies the criteria typical for immune checkpoint research and small-molecule or biologic inhibitor screening in drug discovery workflows.
Email: support@cusabio.com
Distributors Worldwide